The effect of Semelil(Angipars)on bone resorption and bone formation markers in type 2 diabetic patients
Abstract:
Background and purpose of the study: Diabetes mellitus type 2 has been recognized as a major risk factor for osteoporosis and bone turnover is affected in diabetic patients by different mechanisms. As the morbidity, mortality and financial cost related to osteoporosis are expected to rise in Iran in coming years, there is a need for alternative and complementary pharmacotherapy which has better results and less complication. This study was designed to investigate the effect of a new herbal drug, Semelil(Angipars), on bone resorption and bone formation markers.
Methods: This randomized, double- blind clinical trial, was conducted with 61 diabetic patients who were divided into two groups, intervention group with 100mg oral Angipars twice a day and the placebo group. Baseline and after tree months laboratory tests including bone alk-ph, osteocalcin, serum tumor necrotizing factor α (TNF-α), urine calcium, urine creatinin and urine pyridinoline were performed.
Result: 31 patients in study group and 30 patients in control group were included. The mean age of the study population and the mean disease duration was respectively 51.8 ± 6.2 and 7.5 ± 4.7 years with no significant differences between patients and controls. There was no significant change in bone resorption and bone formation markers in the treatment group who received Semelil(Angipars).
Conclusion: It might be different unknown mechanisms of Semelil(Angipars) on bone turnover process which need more studies and more time to be discovered.
Keywords: Diabetes mellitus type 2, Bone turnover markers, Angipars, Semelil
|
||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||
